Experience of bevacizumab in a patient with colorectal cancer after renal transplantation

Musri F. Y., Mutlu H., Eryilmaz M. K., Salim D. K., COŞKUN H. Ş.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.11, sa.4, ss.1018-1020, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 4
  • Basım Tarihi: 2015
  • Doi Numarası: 10.4103/0973-1482.168996
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1018-1020
  • Anahtar Kelimeler: Bevacizumab, metastatic colorectal cancer, renal transplantation, THROMBOTIC MICROANGIOPATHY, FLUOROURACIL, OXALIPLATIN, LEUCOVORIN
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Bevacizumab is a drug that is widely used for the first-line treatment of metastatic colorectal cancer (mCRC). Bevacizumab neutralizes vascular endothelial growth factor and can lead to proteinuria and renal damage. In this case, experience on full dose short-time treatment of bevacizumab in a patient under immunosuppressive treatment for renal transplantation with chronic renal failure has been shared. The patients were diagnosed with mCRC 7 months ago. The patient had multiple liver metastases at the time of the diagnosis. He had a history of renal transplantation 2 years ago because of renal failure, and he had been under immunosuppressive treatment for this reason. 5-fluorouracil-leucovorin-irinotecan -bevacizumab regimen was begun for the treatment of mCRC. The dose of bevacizumab was 5 mg/kg/day for 14 days. There was 2.5 g/day of proteinuria at the start of the treatment. However, renal dysfunction progressed, and proteinuria increased to 4 g/day in the 3 (rd) month of treatment. In this case, the experience of using bevacizumab in a patient under immunosuppressive treatment for renal transplantation with chronic failure has been presented.